These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20582870)

  • 1. The 'retro-design' concept for novel kinase inhibitors.
    Müller G; Sennhenn PC; Woodcock T; Neumann L
    IDrugs; 2010 Jul; 13(7):457-66. PubMed ID: 20582870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors.
    Liao JJ
    J Med Chem; 2007 Feb; 50(3):409-24. PubMed ID: 17266192
    [No Abstract]   [Full Text] [Related]  

  • 3. Peptides targeting protein kinases: strategies and implications.
    Kaidanovich-Beilin O; Eldar-Finkelman H
    Physiology (Bethesda); 2006 Dec; 21():411-8. PubMed ID: 17119154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The synergy between combinatorial chemistry and high-throughput screening.
    Diller DJ
    Curr Opin Drug Discov Devel; 2008 May; 11(3):346-55. PubMed ID: 18428088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved lead-finding for kinase targets using high-throughput docking.
    McInnes C
    Curr Opin Drug Discov Devel; 2006 May; 9(3):339-47. PubMed ID: 16729730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase inhibitors: insights into drug design from structure.
    Noble ME; Endicott JA; Johnson LN
    Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural approaches to obtain kinase selectivity.
    Norman RA; Toader D; Ferguson AD
    Trends Pharmacol Sci; 2012 May; 33(5):273-8. PubMed ID: 22503441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MALDI-TOF mass-spectrometry-based versatile method for the characterization of protein kinases.
    Kondo N; Nishimura S
    Chemistry; 2009; 15(6):1413-21. PubMed ID: 19115309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress in the design of selective ATP-competitive kinase inhibitors].
    Deng XQ; Xiang ML; Jia R; Yang SY
    Yao Xue Xue Bao; 2007 Dec; 42(12):1232-6. PubMed ID: 18338633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent trends in library design: 'rational design' revisited.
    Schnur DM
    Curr Opin Drug Discov Devel; 2008 May; 11(3):375-80. PubMed ID: 18428091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The identification of new protein kinase inhibitors as targets in modern drug discovery.
    Akritopoulou-Zanze I
    IDrugs; 2006 Jul; 9(7):481-7. PubMed ID: 16821161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knowledge-based scoring functions in drug design. 1. Developing a target-specific method for kinase-ligand interactions.
    Xue M; Zheng M; Xiong B; Li Y; Jiang H; Shen J
    J Chem Inf Model; 2010 Aug; 50(8):1378-86. PubMed ID: 20681607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment-based approaches to the discovery of kinase inhibitors.
    Mortenson PN; Berdini V; O'Reilly M
    Methods Enzymol; 2014; 548():69-92. PubMed ID: 25399642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural biology contributions to tyrosine kinase drug discovery.
    Cowan-Jacob SW; Möbitz H; Fabbro D
    Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence-based protein kinase inhibition: applications for drug development.
    Wexler I; Niv M; Reuveni H
    Biotechniques; 2005 Oct; 39(10 Suppl):S575-6. PubMed ID: 18957040
    [No Abstract]   [Full Text] [Related]  

  • 16. Halogen bonding--a novel interaction for rational drug design?
    Lu Y; Shi T; Wang Y; Yang H; Yan X; Luo X; Jiang H; Zhu W
    J Med Chem; 2009 May; 52(9):2854-62. PubMed ID: 19358610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D-QSAR CoMFA analysis of C5 substituted pyrrolotriazines as HER2 (ErbB2) inhibitors.
    Awale M; Mohan CG
    J Mol Graph Model; 2008 Apr; 26(7):1169-78. PubMed ID: 18055238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational design of inhibitors that bind to inactive kinase conformations.
    Liu Y; Gray NS
    Nat Chem Biol; 2006 Jul; 2(7):358-64. PubMed ID: 16783341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights for the development of specific kinase inhibitors by targeted structural genomics.
    Fedorov O; Sundström M; Marsden B; Knapp S
    Drug Discov Today; 2007 May; 12(9-10):365-72. PubMed ID: 17467572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisubstrate inhibitors of protein kinases: from principle to practical applications.
    Lavogina D; Enkvist E; Uri A
    ChemMedChem; 2010 Jan; 5(1):23-34. PubMed ID: 19774589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.